Fed. Circ. Clears Apotex In Neulasta Biosimilar Patent Row
A Federal Circuit panel upheld a lower court ruling that found Apotex Inc. did not infringe a patent covering Amgen Inc.'s blockbuster drug Neulasta, while clarifying the amount of weight courts...To view the full article, register now.
Already a subscriber? Click here to view full article